Die Auswirkungen von Bronchipret® auf die Atemmechanik bei dämpfigen Pferden (COPD) und die orale Verträglichkeit

C.O.P.D is a common pulmonary disorder of stabled horses. Many studies have identified that fungal spores and bacteria originating from poor quality hay and straw bedding are factors that trigger the clinical expression of the syndrome. Clinical symptoms in affected horses often improve when hay is soaked in water and when straw bedding is replaced by peat, paper or sawdust. The disposal of these bedding materials provide problems as dirty bedding have no direct value in agriculture as fertiliser. Moreover as most horses in Austria are kept in livery stables, it is difficult to organise conditions that suit every horse and owner. Therefore environmental conditions often cannot be optimised for horses suffering obstructive airway diseases and other management strategies must be found. Due to down regulation of the b2 receptors in airways after a relative short period of b-agonist treatment, these drugs are not suited for long lasting symptomatic treatment. At present, despite its side effects, prednisolon therapy appears the best choice for long lasting treating of severe cases. It would be helpful to enlarge the therapeutic possibilities with new active substances. Bronchipret®, a herbal product containing extracts of Thymus vulgaris and Primula veris, is a popular medicine for treatment of human bronchitis. Pharmacological studies have showed that thymol, one of the major ingredients of Bronchipret® has bronchospatic activity and antiinflammatory activities. Moreover the substance has mucolytic, antioxidant antiviral and antibacterial activity. Aim of the study The purpose of the trial is to show improvement of pulmonary respiratory parameters of horses suffering from COPD after treatment with Bronchipret® and to demonstrate the oral tolerance.

Klinisches Zentrum für Pferde

Bionorica SE
Funktion: Partner